ArticleOncotarget2014
Prognostic impact of a compartment-specific angiogenic marker profile in patients with pancreatic cancer.
Article in Oncotarget, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Diagnostic valuation of MMP family members as biomarkers for pancreatic cancer: a systematic review and meta-analysis.Biomarkers in medicine · 2025Pooled it
- Diagnostic Accuracy of Blood-based Biomarkers for Pancreatic Cancer: A Systematic Review and Meta-analysis.Cancer research communications · 2022Pooled it
- Immune Markers and Risk of Pancreatic Cancer in the European EPIC Cohort.International journal of cancer · 2026Article
- Diagnostic and Prognostic Values of Bile Biomarkers for Malignant Biliary Stenosis.Liver international : official journal of the International Association for the Study of the Liver · 2026Article
- Emerging horizons on molecular and circulating biomarkers in pancreatic adenocarcinoma.Frontiers in oncology · 2024Review
- Genome-Wide Association Analysis of Muscle pH in Texel Sheep × Altay Sheep FAnimals : an open access journal from MDPI · 2023Article
- Biomarkers in the diagnosis of pancreatic cancer: Are we closer to finding the golden ticket?World journal of gastroenterology · 2021Review
- Extracellular Matrices and Cancer-Associated Fibroblasts: Targets for Cancer Diagnosis and Therapy?Cancers · 2021Review
- MMP7 as a potential biomarker of colon cancer and its prognostic value by bioinformatics analysis.Medicine · 2021Article
- Pancreatic Cancer and Platelets Crosstalk: A Potential Biomarker and Target.Frontiers in cell and developmental biology · 2021Review
- TNM staging for GIT cancers is correlated with the level of MMPs and TGF-β1.Clinical and experimental medicine · 2020Article
- Circulating tumour-derived KRAS mutations in pancreatic cancer cases are predominantly carried by very short fragments of cell-free DNA.EBioMedicine · 2020Article
- Matrix Metalloproteases in Pancreatic Ductal Adenocarcinoma: Key Drivers of Disease Progression?Biology · 2020Review
- Serum PlGF and EGF are independent prognostic markers in non-metastatic colorectal cancer.Scientific reports · 2019Article
- Pancreatic cancer biomarker detection by two support vector strategies for recursive feature elimination.Biomarkers in medicine · 2019Article
- Review
- Advances in pancreatic cancer biomarkers.Oncology reviews · 2019Article
- Review
- Angiogenesis and Anti-Angiogenic Therapy in Gastric Cancer.International journal of molecular sciences · 2017Review
- The role ofActa medica Lituanic · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer consists of a heterogenous bulk of tumor cells and stroma cells which contribute to tumor progression by releasing angiogenic factors. Those factors can be detected as circulating serum factors. We performed a compartment-specific analysis of tumor-derived and stroma-derived angiogenic factors to identify biomarkers and molecular targets for the treatment of pancreatic cancer. Kryo-frozen tissue from primary ductal adenocarcinomas (n = 51) was laser-microdissected to isolate tumor and stroma tissue. Expression of 17 angiogenic factors (angiopoietin-2, follistatin, GCSF, HGF, interleukin-8, leptin, PDGF-BB, PECAM-1, VEGF, matrix metalloproteinase -1, -2, -3, -7, -9, -10, -12, and -13) was analyzed using a multiplex elisa assay for tissue-derived proteins and corresponding serum. Our study reveals a compartment-specific expression profile for several angiogenic factors and matrix metalloproteinases. ROC analysis of corresponding serum samples reveals MMP-7 and MMP-12 as strong classifiers for the diagnosis of patients with pancreatic cancer vs. healthy control donors. High expression of tumor-derived PDGF-BB and MMP-1 correlates with prolonged survival in univariate and multivariate analysis. In conclusion, a distinct expression patterns for angiogenic cytokines and MMPs in pancreatic cancer and surrounding stroma may implicate them as novel targets for cancer treatment. Tumor-derived PDGF-BB and MMP-1 are significant and independent prognostic markers for poor survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.